Figure 3
MR imaging performed 2 days after the last CT coronal T2-weighted sequence. The cerebellum is still enlarged, and shows hyperintensity of the cortex, due to oedema (?).
preparation used for the intrathecal treatment was checked (100 mg with 5 ml of solvent) and the dose (1.6 ml for 30 mg) administered was correct.
The mechanisms involved in this CNS toxicity could be toxic exposure of the cerebellum to ara-C. As has been suggested for methotrexate, the presence of overt meningeal leukemia may predispose to the increased CSF concentration of ara-C and to the development of Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation Leukemia (2002) 16, 2455-2456. doi:10.1038/sj.leu.2402716
TO THE EDITOR
Recently, the therapeutic effect of arsenic trioxide (As 2 O 3 ) has been proven in acute promyelocytic leukemia (APL) patients in relapse and at diagnosis by several groups in China. 1 On the basis of the impressive results obtained in the pilot trial of the Memorial Sloan-Kettering Cancer Center, 2 92% complete remission (CR) rate in relapsed APL patients, in the United States a multicenter study has been conducted to evaluate the efficacy and tolerability of As 2 O 3 for remission induction and consolidation in a larger population of APL patients who had relapsed from prior retinoic and anthracycline-based chemotherapy. 3 In this study the authors reported an 85% CR rate with a relapse free survival rate at 18 months of 56%.
Here, we report a patient with APL who was treated with As 2 O 3 while in second relapse after allogeneic bone marrow transplantation. The patient, a 53-year-old male, was diagnosed in July 1998 with APL, at diagnosis cytogenetic showed a normal karyotype while with reverse transcriptase polymerase chain reaction (RT-PCR) assay a PML/RAR␣ transcript with a bcr3 isoform was identified. The patient was treated according to the GIMEMA AIDA trial 4 Leukemia neurotoxicity. [2] [3] The CSF clearance of ara-C is similar to that of the CSF bulk flow rate. Furthermore, there is little conversion of ara-C to uracile arabinoside in the brain and CSF. Thus, the obstructed CSF flow due to the massive number of leukemic cells and their lysis could result in a high CSF concentration of ara-C and/or a prolonged exposure of cerebellum to ara. C. Unfortunately, the methotrexate or ara-CTP levels were not measured in the patient' CSF. To our knowledge, neurotoxicity due to intrathecal ara-C has not been previously reported. This observation confirms that protocols for overt meningeal leukemia should be designed with lower rather than higher dosages of intrathecal drugs, not only for methotrexate but also for ara-C. We would like to caution against the systematic use of ara-C in the initial intrathecal treatment of these overt CNS leukemias. plete remission after induction treatment with a persistence of the transcript at the RT-PCR. The molecular complete remission was obtained after the second consolidation therapy.
After 12 months from CR, 8 months from the PML/RAR␣ negativity, while on maintenance therapy with alternating methotrexate, 6-mercaptopurine, and all-trans retinoic acid (ATRA) according to the protocol, the patient showed a molecular relapse of the disease detected in two bone marrow samples collected 3 weeks apart. He received ATRA for 1 month as salvage treatment followed by chemotherapy with mitoxantrone and high-dose Ara-C for 4 consecutive days. As soon as a second molecular remission was achieved he underwent allogeneic bone marrow transplantation from an HLA-identical brother. The conditioning treatment consisted of cyclophosphamide and TBI; cyclosporine and short-term methotrexate were administered for graft-versus-host disease (GVHD) prophylaxis. The clinical course was unremarkable, the patient did not experience acute or chronic GVHD and cyclosporine was slowly tapered until discontinuation at the 7th month. At the posttransplant restaging, 3 months after bone marrow reinfusion, he was in complete hematological and molecular remission and bone marrow showed a complete donor chimerism.
Eleven months from transplant a second relapse occurred, bone marrow trephine showing the presence of a diffuse interstitial infiltration of abnormal promyelocytes. Conventional cytogenetic analysis revealed 46,XY while the PML/RAR␣ fusion gene was detected both at RT-PCR and interphase FISH analysis. A mixed chimerism was demonstrated in the bone marrow mononuclear cell sample, with 50% of host cells. The peripheral blood examination revealed a WBC 5.7 × 10 9 /l; Hb 11 g/dl, platelets 84 × 10 9 /l; no blasts were observed in the peripheral blood smears.
Leukemia
After written informed consent was obtained the patient received As 2 O 3 as salvage treatment, the drug being administered at the dosage of 10 mg daily for 40 days. To prevent the development of symptoms identical to the retinoic acid syndrome, dexamethasone at the dosage of 25 mg/day was added in the first 10 days of treatment.
Bone marrow aspirate performed after 15 days from the beginning of treatment, to assess drug efficacy, showed the disappearance of visible leukemic cells while the PML/RAR␣ transcript persisted. The patient did not experienced extra-haematological toxicity. As regards hematological toxicity we observed a transient grade 1 neutropenia, according to WHO criteria, and a grade 2 thrombocytopenia; the patient showed complete platelet recovery within 10 days from therapy discontinuation. The bone marrow evaluation at the end of treatment confirmed the morphological CR, PML/RAR␣ was not detected by RT-PCR, and a fully donor chimerism was restored. The patient was consolidated with additional two courses of As 2 O 3 for 25 days at the same dosage of 10 mg/day every 2 months without any hematological or extrahematological toxicity.
After 14 months the patient is still in a third morphological and molecular remission maintaining complete donor chimerism.
The analysis of the clinical history of this patient shows that the best salvage treatment approach was difficult to establish since he had already received an allogeneic bone marrow transplant.
Donor lymphocyte infusion to induce a graft-versus-leukemia (GVL) effect is a feasible approach in patients relapsing after allogeneic bone marrow transplant. The role of this procedure in recurrent acute myeloid leukemias has not been well established and no data regarding the effect in APL have been reported. Furthermore, our patient would not have experienced any advantage from GVL reactivity after the allogeneic transplant. In fact, he did not develop GVHD after allogeneic transplant, even if the possibility of a GVL effect cannot be excluded in the absence of GVHD for reactivity against unique leukemia-associated antigens. In addition, the duration of the second CR was shorter than the first one.
Morbidity of salvage treatment with cytotoxic drugs is potentially elevated in such heavily pretreated patients, and in addition, intensive chemotherapy could determine myelosuppression of the residual donor marrow.
Both ATRA and As 2 O 3 have been considered in the treatment of patients with relapsed disease. Although ATRA in monochemotherapy induces CR by morphologic criteria, the neoplastic clone is not eliminated when the drug is used as a single agent particularly in patients with overt disease. 5 Furthermore, remissions have typically lasted no more than a few months, due to the rapid occurrence of retinoid resistance. 6 Our patient had already been exposed twice to ATRA having received the drug within the previous 12 months thus enhancing the risk of development of ATRA resistance.
As 2 O 3 has been established as a highly effective therapy for patients with relapsed APL and recent observations indicate that this agent is more potent than ATRA for inducing molecular remission. To our knowledge, this is the first report describing the role of As 2 O 3 in obtaining a sustained complete molecular remission in an APL patient relapsing after allogeneic bone marrow transplantation. Although 3 CR in five cases relapsing after BMT have been recently reported in the United States multicenter trial, the type of bone marrow transplant, the molecular status after salvage treatment and the CR duration have not been reported. 3 The role of As 2 O 3 in triggering cell apoptosis and inducing partial differentiation has been demonstrated. 7 In the present case the suppression of the abnormal clone after the first course of therapy allowed not only a long-lasting molecular remission but a conversion to complete donor chimerism to be obtained. The patient did not experience myelosuppression and GVHD was not observed during the reconstitution of donor bone marrow chimerism.
Finally, a body of life-threatening adverse events has been frequently reported during treatment with As 2 O 3 ; the tolerance to therapy in our case was impressive without any sign of toxicity. 
